The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | How has COVID-19 affected the myeloma field?
Daniel Auclair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, shares his thoughts on what the COVID-19 pandemic has taught us and how it will continue to affect the myeloma field going forward. For example, the widespread introduction of telemedicine has completely changed access to doctors and will likely be an approach used for a long time to come. It has additionally impacted the research focuses in the myeloma field, with more thought going into treatment options that could minimize the number of clinic visits. Dr Auclair believes much needed developments have been brought about by the pandemic. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
